Inhibitory effects of a peptide-fusion protein (Latarcin-PAP1-Thanatin) against chikungunya virus
Chikungunya virus (CHIKV) outbreaks have led to a serious economic burden, as the available treatment strategies can only alleviate disease symptoms, and no effective therapeutics or vaccines are currently available for human use. Here, we report the use of a new cost-effective approach involving pr...
Saved in:
Main Authors: | Rothan, H.A., Bahrani, H., Shankar, E.M., Rahman, N.A., Yusof, R. |
---|---|
Format: | Article |
Language: | English |
Published: |
2017
|
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Identification of natural antimicrobial agents to treat dengue infection: In vitro analysis of latarcin peptide activity against dengue virus
by: Rothan, H.A., et al.
Published: (2017) -
A combination of doxycycline and ribavirin alleviated chikungunya infection
by: Rothan, H.A., et al.
Published: (2017) -
Interaction of Phage Display Peptides to Chikungunya and Zika Virus Recombinant Proteins
by: Nur Izzah, Ismadol
Published: (2024) -
Identification of Peptide Leads to Inhibit Hepatitis C Virus: Inhibitory Effect of Plectasin Peptide Against Hepatitis C Serine Protease
by: Abdulrahman, A.Y., et al.
Published: (2017) -
Mefenamic acid in combination with ribavirin shows significant effects in reducing chikungunya virus infection in vitro and in vivo
by: Rothan, H.A., et al.
Published: (2017)